{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:11:11Z","timestamp":1790140271395,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant 81470297"],"award-info":[{"award-number":["grant 81470297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant 81770129"],"award-info":[{"award-number":["grant 81770129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471911"],"award-info":[{"award-number":["81471911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant 81471911"],"award-info":[{"award-number":["grant 81471911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA187276"],"award-info":[{"award-number":["R21CA187276"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cincinnati Children's Hospital Research Foundation the Leukemia Research Foundation the OCRA"},{"name":"the Cincinnati Children's Hospital Research Foundation"},{"name":"Personalized Medicines--Molecular Signature-based Drug Discovery and Development Strategic Priority Research Program of the Chinese Academy of Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41375-019-0456-2","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T10:04:21Z","timestamp":1554804261000},"page":"2585-2598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints"],"prefix":"10.1038","volume":"33","author":[{"given":"Yunzhu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yile","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894\u2013907.","journal-title":"Lancet"},{"issue":"Suppl","key":"456_CR2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.clml.2016.02.007","volume":"16","author":"NJ Short","year":"2016","unstructured":"Short NJ, Ravandi F. Acute myeloid leukemia: past, present, and prospects for the future. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S25\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"456_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.","journal-title":"BMC Med"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.21037\/tcr.2017.02.14","volume":"6","author":"E Nagler","year":"2017","unstructured":"Nagler E, Xavier MF, Frey N. Updates in immunotherapy for acute myeloid leukemia. Transl Cancer Res. 2017;6:86\u201392.","journal-title":"Transl Cancer Res"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2174\/1389450117999151116144835","volume":"18","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS. Editorial: targets for immunotherapy in acute leukemia. Curr Drug Targets. 2017;18:256.","journal-title":"Curr Drug Targets"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566\u201381.","journal-title":"Nat Rev Cancer"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","volume":"46","author":"X Zhu","year":"2014","unstructured":"Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014;46:287\u201393.","journal-title":"Nat Genet"},{"key":"456_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4469","volume":"5","author":"BG Mar","year":"2014","unstructured":"Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014;5:3469.","journal-title":"Nat Commun"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1182\/blood-2017-03-775569","volume":"130","author":"BG Mar","year":"2017","unstructured":"Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017;130:2631\u201341.","journal-title":"Blood"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.18632\/oncotarget.6259","volume":"7","author":"H Xiao","year":"2016","unstructured":"Xiao H, Wang LM, Luo Y, Lai X, Li C, Shi J, et al. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016;7:2696\u2013708.","journal-title":"Oncotarget"},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1182\/blood-2012-02-412379","volume":"120","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem\/progenitor cells. Blood. 2012;120:1118\u201329.","journal-title":"Blood"},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"17636","DOI":"10.1073\/pnas.0506350102","volume":"102","author":"M Li","year":"2005","unstructured":"Li M, Phatnani HP, Guan Z, Sage H, Greenleaf AL, Zhou P. Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1. Proc Natl Acad Sci USA. 2005;102:17636\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1073\/pnas.0915033107","volume":"107","author":"M Hu","year":"2010","unstructured":"Hu M, Sun XJ, Zhang YL, Kuang Y, Hu CQ, Wu WL, et al. Histone H3 lysine 36 methyltransferase Hypb\/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci USA. 2010;107:2956\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1128\/MCB.23.12.4207-4218.2003","volume":"23","author":"NJ Krogan","year":"2003","unstructured":"Krogan NJ, Kim M, Tong A, Golshani A, Cagney G, Canadien V, et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol. 2003;23:4207\u201318.","journal-title":"Mol Cell Biol"},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/leu.2016.134","volume":"30","author":"H Parker","year":"2016","unstructured":"Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, et al. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia. 2016;30:2179\u201386.","journal-title":"Leukemia"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1093\/emboj\/18.13.3564","volume":"18","author":"CL Dobson","year":"1999","unstructured":"Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 1999;18:3564\u201374.","journal-title":"EMBO J"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24:1785\u20138.","journal-title":"Leukemia"},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/leu.2017.339","volume":"32","author":"J Bu","year":"2018","unstructured":"Bu J, Chen A, Yan X, He F, Dong Y, Zhou Y, et al. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. Leukemia. 2018;32:890\u20139.","journal-title":"Leukemia"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","volume":"3","author":"J Bartek","year":"2003","unstructured":"Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421\u20139.","journal-title":"Cancer Cell"},{"key":"456_CR21","first-page":"508","volume":"2","author":"D Schnerch","year":"2012","unstructured":"Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M, et al. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2:508\u201328.","journal-title":"Am J Cancer Res"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0027-5107(96)00138-8","volume":"372","author":"PR Andreassen","year":"1996","unstructured":"Andreassen PR, Martineau SN, Margolis RL. Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. Mutat Res. 1996;372:181\u201394.","journal-title":"Mutat Res"},{"key":"456_CR23","first-page":"7660","volume":"61","author":"PR Andreassen","year":"2001","unstructured":"Andreassen PR, Lacroix FB, Lohez OD, Margolis RL. Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res. 2001;61:7660\u20138.","journal-title":"Cancer Res"},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992\u20133000.","journal-title":"Mol Cancer Ther"},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-10-0928","volume":"10","author":"TJ Guzi","year":"2011","unstructured":"Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011;10:591\u2013602.","journal-title":"Mol Cancer Ther"},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/leu.2011.392","volume":"26","author":"CC Porter","year":"2012","unstructured":"Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012;26:1266\u201376.","journal-title":"Leukemia"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1128\/MCB.23.10.3607-3622.2003","volume":"23","author":"FX Li","year":"2003","unstructured":"Li FX, Zhu JW, Hogan CJ, DeGregori J. Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1\/E2F2 mutant mice. Mol Cell Biol. 2003;23:3607\u201322.","journal-title":"Mol Cell Biol"},{"key":"456_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s004120050256","volume":"106","author":"MJ Hendzel","year":"1997","unstructured":"Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348\u201360.","journal-title":"Chromosoma"},{"key":"456_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1083\/jcb.122.2.295","volume":"122","author":"N Chaudhary","year":"1993","unstructured":"Chaudhary N, Courvalin JC. Stepwise reassembly of the nuclear envelope at the end of mitosis. J Cell Biol. 1993;122:295\u2013306.","journal-title":"J Cell Biol"},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nm.4210","volume":"22","author":"OA Guryanova","year":"2016","unstructured":"Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22:1488\u201395.","journal-title":"Nat Med"},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S Gollner","year":"2016","unstructured":"Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2016;23:69\u201378.","journal-title":"Nat Med"},{"key":"456_CR32","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1073\/pnas.1116345109","volume":"109","author":"J Speroni","year":"2012","unstructured":"Speroni J, Federico MB, Mansilla SF, Soria G, Gottifredi V. Kinase-independent function of checkpoint kinase 1 (Chk1) in the replication of damaged DNA. Proc Natl Acad Sci USA. 2012;109:7344\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/cdd.2011.48","volume":"18","author":"Z Wu","year":"2011","unstructured":"Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011;18:1771\u20139.","journal-title":"Cell Death Differ"},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell. 2015;28:557\u201368.","journal-title":"Cancer Cell"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/blood-2011-07-367557","volume":"119","author":"R Tibes","year":"2012","unstructured":"Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, et al. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012;119:2863\u201372.","journal-title":"Blood"},{"key":"456_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/pbc.25081","volume":"61","author":"JT Caldwell","year":"2014","unstructured":"Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer. 2014;61:1767\u201373.","journal-title":"Pediatr Blood Cancer"},{"key":"456_CR37","doi-asserted-by":"publisher","first-page":"28001","DOI":"10.18632\/oncotarget.4830","volume":"6","author":"JB Ford","year":"2015","unstructured":"Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015;6:28001\u201310.","journal-title":"Oncotarget"},{"key":"456_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.leukres.2017.11.004","volume":"64","author":"TB Garcia","year":"2018","unstructured":"Garcia TB, Fosmire SP, Porter CC. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res. 2018;64:30\u20133.","journal-title":"Leuk Res"},{"key":"456_CR39","first-page":"1097","volume":"45","author":"K Tamura","year":"2015","unstructured":"Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015;45:1097\u2013102.","journal-title":"Jpn J Clin Oncol"},{"key":"456_CR40","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34:4354\u201361.","journal-title":"J Clin Oncol"},{"key":"456_CR41","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","volume":"24","author":"E Mendez","year":"2018","unstructured":"Mendez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, et al. A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2018;24:2740\u20138.","journal-title":"Clin Cancer Res"},{"key":"456_CR42","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34:4371\u201380.","journal-title":"J Clin Oncol"},{"key":"456_CR43","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/1535-7163.MCT-13-0424","volume":"12","author":"AA Van Linden","year":"2013","unstructured":"Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013;12:2675\u201384.","journal-title":"Mol Cancer Ther"},{"key":"456_CR44","doi-asserted-by":"publisher","first-page":"50719","DOI":"10.18632\/oncotarget.9368","volume":"7","author":"J Li","year":"2016","unstructured":"Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K. SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget. 2016;7:50719\u201334.","journal-title":"Oncotarget"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0456-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:08:42Z","timestamp":1650431322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0456-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}